Aethlon Medical engages with authorities on Hemopurifier for Ebola
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 20 2024
0mins
Aethlon Medical's stock price fell by 13.95% as it crossed below the 5-day SMA amid broader market gains. The company is preparing to engage with global healthcare and regulatory authorities regarding the investigational use of its Hemopurifier technology in response to the Ebola outbreak in the Democratic Republic of the Congo and Uganda. This proactive approach highlights the potential of the Hemopurifier, which has received FDA's Breakthrough Device Designation, to address urgent health needs, despite the current stock decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AEMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AEMD
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aethlon Medical Prepares to Address Ebola Outbreak with Hemopurifier Technology
- Technological Engagement: Aethlon Medical is preparing to engage with global healthcare and regulatory authorities regarding the investigational use of its Hemopurifier technology in response to the Ebola outbreak in the Democratic Republic of the Congo and Uganda, demonstrating the company's proactive approach to public health crises.
- Stock Price Reaction: Following this announcement, AEMD's stock price rose by 6.36% in pre-market trading to $2.34, reflecting market optimism regarding the potential of the company's technology in addressing urgent health needs.
- FDA Certification Advantage: The Hemopurifier has received FDA's Breakthrough Device Designation for treating advanced cancer patients unresponsive to standard therapies and for life-threatening viruses not addressed by approved treatments, enhancing its competitive position in the medical market.
- Clinical Application Case: In 2014, the Hemopurifier was used on a critically ill Ebola patient, resulting in a viral load reduction from approximately 400,000 to 1,000 copies per milliliter after a single 6.5-hour treatment, showcasing its effectiveness in emergency situations and supporting its clinical application potential.
See More
Aethlon Medical Monitors Ebola Outbreak Developments
- Ebola Outbreak Monitoring: Aethlon Medical is actively monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, preparing to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology, demonstrating the company's commitment to addressing public health crises.
- Hemopurifier Treatment Efficacy: During the 2014 Ebola outbreak, the Hemopurifier was successfully administered to a critically ill patient, reducing their viral load from 400,000 to 1,000 copies per milliliter, with the virus becoming undetectable five days post-treatment, indicating the device's potential efficacy in emergency situations.
- FDA Regulatory Pathway: The U.S. FDA has approved an Investigational Device Exemption for the Hemopurifier, establishing a regulatory pathway for its investigational use in Ebola-infected individuals in the U.S., highlighting the technology's potential in addressing life-threatening diseases.
- Future Development Plans: Aethlon Medical stated it will continue to monitor the evolving Ebola situation and respond to inquiries from treating clinicians, emphasizing its strategic importance in combating viral threats where approved therapies may be limited.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present at the Life Sciences Investor Forum on March 12, 2026, providing real-time interaction opportunities with investors, thereby enhancing the company's visibility and credibility among stakeholders.
- Clinical Trial Progress: The active progression of Cohort 2 in the Australian oncology trial reflects the company's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's future potential.
- Scientific Research Advancement: Continued advancements in the company's extracellular vesicle research platform, including Long COVID data submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, opening new market opportunities for the company.
- Technology Development: Ongoing evaluation of Hemopurifier® compatibility with a simplified blood treatment system is expected to support broader clinical applications, further enhancing the company's competitiveness in the medical device market.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present live at the Life Sciences Investor Forum on March 12, 2026, hosted by VirtualInvestorConferences.com, which is expected to attract significant attention from investors and industry professionals, thereby enhancing the company's visibility among investors.
- Clinical Progress Update: The active progression of Cohort 2 in the Australian oncology trial reflects Aethlon's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's research and development capabilities.
- Scientific Research Advancement: Continued advancements in Aethlon's preclinical extracellular vesicle research platform, particularly with Long COVID data published on bioRxiv and submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, potentially attracting more investor interest in its R&D direction.
- Ongoing Technology Development: The evaluation of Hemopurifier® compatibility with a simplified blood treatment system is ongoing, aimed at supporting broader clinical applications, which not only enhances the product's market competitiveness but may also open new revenue growth opportunities for the company.
See More
Aethlon Medical Prepares to Address Ebola Outbreak with Hemopurifier Technology
- Technological Engagement: Aethlon Medical is preparing to engage with global healthcare and regulatory authorities regarding the investigational use of its Hemopurifier technology in response to the Ebola outbreak in the Democratic Republic of the Congo and Uganda, demonstrating the company's proactive approach to public health crises.
- Stock Price Reaction: Following this announcement, AEMD's stock price rose by 6.36% in pre-market trading to $2.34, reflecting market optimism regarding the potential of the company's technology in addressing urgent health needs.
- FDA Certification Advantage: The Hemopurifier has received FDA's Breakthrough Device Designation for treating advanced cancer patients unresponsive to standard therapies and for life-threatening viruses not addressed by approved treatments, enhancing its competitive position in the medical market.
- Clinical Application Case: In 2014, the Hemopurifier was used on a critically ill Ebola patient, resulting in a viral load reduction from approximately 400,000 to 1,000 copies per milliliter after a single 6.5-hour treatment, showcasing its effectiveness in emergency situations and supporting its clinical application potential.
See More
Aethlon Medical Monitors Ebola Outbreak Developments
- Ebola Outbreak Monitoring: Aethlon Medical is actively monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, preparing to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology, demonstrating the company's commitment to addressing public health crises.
- Hemopurifier Treatment Efficacy: During the 2014 Ebola outbreak, the Hemopurifier was successfully administered to a critically ill patient, reducing their viral load from 400,000 to 1,000 copies per milliliter, with the virus becoming undetectable five days post-treatment, indicating the device's potential efficacy in emergency situations.
- FDA Regulatory Pathway: The U.S. FDA has approved an Investigational Device Exemption for the Hemopurifier, establishing a regulatory pathway for its investigational use in Ebola-infected individuals in the U.S., highlighting the technology's potential in addressing life-threatening diseases.
- Future Development Plans: Aethlon Medical stated it will continue to monitor the evolving Ebola situation and respond to inquiries from treating clinicians, emphasizing its strategic importance in combating viral threats where approved therapies may be limited.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present at the Life Sciences Investor Forum on March 12, 2026, providing real-time interaction opportunities with investors, thereby enhancing the company's visibility and credibility among stakeholders.
- Clinical Trial Progress: The active progression of Cohort 2 in the Australian oncology trial reflects the company's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's future potential.
- Scientific Research Advancement: Continued advancements in the company's extracellular vesicle research platform, including Long COVID data submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, opening new market opportunities for the company.
- Technology Development: Ongoing evaluation of Hemopurifier® compatibility with a simplified blood treatment system is expected to support broader clinical applications, further enhancing the company's competitiveness in the medical device market.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present live at the Life Sciences Investor Forum on March 12, 2026, hosted by VirtualInvestorConferences.com, which is expected to attract significant attention from investors and industry professionals, thereby enhancing the company's visibility among investors.
- Clinical Progress Update: The active progression of Cohort 2 in the Australian oncology trial reflects Aethlon's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's research and development capabilities.
- Scientific Research Advancement: Continued advancements in Aethlon's preclinical extracellular vesicle research platform, particularly with Long COVID data published on bioRxiv and submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, potentially attracting more investor interest in its R&D direction.
- Ongoing Technology Development: The evaluation of Hemopurifier® compatibility with a simplified blood treatment system is ongoing, aimed at supporting broader clinical applications, which not only enhances the product's market competitiveness but may also open new revenue growth opportunities for the company.
See More
